Table of Content

Open Access iconOpen Access

ORIGINAL ARTICLE

Extensive longitudinal immune profiling reveals sustained innate immune activation in COVID-19 patients with unfavorable outcome

Benjamin Schrijver1,a, Jorn L. J. C. Assmann1,a, Adriaan J. van Gammeren2, Roel C. H. Vermeulen3, Lützen Portengen3, Peter Heukels4, Anton W. Langerak1, Willem A. Dik1, Vincent H. J. van der Velden1,b, Ton A. A. M. Ermens2,b

1 Department of Immunology, Laboratory Medical Immunology, Erasmus MC-University Medical Center Rotterdam, the Netherlands
2 Department of Clinical Chemistry and Hematology, Amphia Hospital, Breda, the Netherlands
3 Department of Population Health Sciences, Institute for Risk Assessment Sciences, University Utrecht, Utrecht, the Netherlands
4 Department of Pulmonology, Amphia Hospital, Breda, the Netherlands
a Shared first author
b Shared last author

* Corresponding Author: Vincent H.J. van der Velden

European Cytokine Network 2020, 31(4), 154-167. https://doi.org/10.1684/ecn.2020.0456

Abstract

COVID-19 differs substantially between individuals, ranging from mild to severe or even fatal. Heterogeneity in the immune response against SARS-COV-2 likely contributes to this. Therefore, we explored the temporal dynamics of key cellular and soluble mediators of innate and adaptive immune activation in relation to COVID-19 severity and progression.
Forty-four patients with a PCR-proven diagnosis of COVID-19 were included. Extensive cellular (leukocytes and T-lymphocyte subsets) and serological immune profiling (cytokines, soluble cell surface molecules, and SARS-CoV-2 antibodies) was performed at hospital admission and every 3-4 days during hospitalization. Measurements and disease outcome were compared between patients with an unfavorable (IC admission and/or death) and favorable (all others) outcome.
Patients with an unfavorable outcome had higher leukocyte numbers at baseline, mostly due to increased neutrophils, whereas lymphocyte and monocyte numbers were reduced. CRP, IL-6, CCL2, CXCL10, and GM-CSF levels were higher at baseline in the unfavorable group, whereas IL-7 levels were lower. SARS-CoV-2 antibodies were more frequently absent in the unfavorable group. Longitudinal analysis revealed delayed kinetics of activated CD4 and CD8 T-lymphocyte subsets in the unfavorable group. Furthermore, whereas CRP, IL-6, CXCL10, and GM-CSF declined in the favorable group, these cytokines declined with delayed kinetics, remained increased, or even increased further in the unfavorable group.
Our data indicate a state of increased innate immune activation in COVID-19 patients with an unfavorable outcome at hospital admission, which remained over time, as compared with patients with a favorable outcome.

Keywords

COVID-19, SARS-CoV-2

Cite This Article

APA Style
Schrijver, B., Assmann, J.L.J.C., Gammeren, A.J.V., Vermeulen, R.C.H., Portengen, L. et al. (2020). Extensive longitudinal immune profiling reveals sustained innate immune activation in COVID-19 patients with unfavorable outcome. European Cytokine Network, 31(4), 154–167. https://doi.org/10.1684/ecn.2020.0456
Vancouver Style
Schrijver B, Assmann JLJC, Gammeren AJV, Vermeulen RCH, Portengen L, Heukels P, et al. Extensive longitudinal immune profiling reveals sustained innate immune activation in COVID-19 patients with unfavorable outcome. Eur Cytokine Network. 2020;31(4):154–167. https://doi.org/10.1684/ecn.2020.0456
IEEE Style
B. Schrijver et al., “Extensive longitudinal immune profiling reveals sustained innate immune activation in COVID-19 patients with unfavorable outcome,” Eur. Cytokine Network, vol. 31, no. 4, pp. 154–167, 2020. https://doi.org/10.1684/ecn.2020.0456



cc Copyright © 2020 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 65

    View

  • 32

    Download

  • 0

    Like

Share Link